Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Depreciation & Amortization (CF) (2017 - 2025)

Dianthus Therapeutics (DNTH) has 7 years of Depreciation & Amortization (CF) data on record, last reported at $27000.0 in Q3 2025.

  • For Q3 2025, Depreciation & Amortization (CF) rose 8.0% year-over-year to $27000.0; the TTM value through Sep 2025 reached $110000.0, up 22.22%, while the annual FY2024 figure was $96000.0, 43.28% up from the prior year.
  • Depreciation & Amortization (CF) reached $27000.0 in Q3 2025 per DNTH's latest filing, down from $30000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $511000.0 in Q1 2022 and bottomed at $18000.0 in Q3 2023.
  • Average Depreciation & Amortization (CF) over 4 years is $183142.9, with a median of $27000.0 recorded in 2025.
  • Peak YoY movement for Depreciation & Amortization (CF): crashed 96.18% in 2023, then skyrocketed 38.89% in 2024.
  • A 4-year view of Depreciation & Amortization (CF) shows it stood at $466000.0 in 2022, then crashed by 95.71% to $20000.0 in 2023, then rose by 30.0% to $26000.0 in 2024, then rose by 3.85% to $27000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $27000.0 in Q3 2025, $30000.0 in Q2 2025, and $27000.0 in Q1 2025.